Goto

Collaborating Authors

 rafter


AI Hot Spots: Where Is Artificial Intelligence Heading Now? - InformationWeek

#artificialintelligence

About a year ago, InformationWeek published a slideshow on 10 Prime Industries for AI Applications. Since then, the artificial intelligence landscape has shifted significantly. To find out how the AI market and how AI is being put to work are changing, InformationWeek reached out to three industry experts: Asheesh Mehra, CEO of AI vendor AntWorks; Christopher Rafter, COO of AI and analytics vendor Inzata; and Seth Earley, author of the forthcoming book The AI-Powered Enterprise. They said that while some enterprises are beginning to see the anticipated benefits of AI, many companies have been disappointed with their early implementations of the technology. "The promise is still far ahead of the reality," said Earley.


Stan Horaczek (Hiding in the CES rafters) on Twitter

#artificialintelligence

So far at #CES2020, it's very obvious that companies will almost always focus on how AI can help people do and consume more. It's never like, "Oh, AI figured out how to handle a lot of stuff. Let's work less and consume less and chill out."


Optimising artificial intelligence in the pharmaceutical industry

#artificialintelligence

Artificial intelligence can be applied to almost every part of the pharma industry. Christopher Rafter discusses its many uses and how the adoption of machine learning will increase in the future. Artificial intelligence (AI) has wide-reaching potential within the pharmaceutical industry, from clinical trials to marketing and sales analytics. Using a machine learning programme can reduce the time spent on examining data, saving money and allowing researchers to focus on other issues. European Pharmaceutical Review's Victoria Rees spoke with Christopher Rafter, Chief Operating Officer (COO) of Inzata Analytics, to discover more about AI in pharma and its capabilities.


Optimising artificial intelligence in the pharmaceutical industry 7wData

#artificialintelligence

Artificial intelligence (AI) has wide-reaching potential within the pharmaceutical industry, from clinical trials to marketing and sales analytics. Using a machine learning programme can reduce the time spent on examining data, saving money and allowing researchers to focus on other issues. European Pharmaceutical Review's Victoria Rees spoke with Christopher Rafter, Chief Operating Officer (COO) of Inzata Analytics, to discover more about AI in pharma and its capabilities. As a machine learning system, AI allows researchers to collect and analyse data effectively, Rafter explained. He described the basic principle; the more data it analyses, the more it will improve.